β-blocker compliance, mortality, and reinfarction: Validation of clinical trial association using insurer claims data

American Journal of Medical Quality

Volumn 24, Issue 6, 2009, Pages 512-519

  Kleiner, Samuel A ^a   Vogt, William B ^b   Gladowski, Patricia ^c   DeVries, Andrea ^d   Levin, Gary ^e   Antonucci, Christopher ^c   Fong, John ^f  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b RAND CORPORATION   (United States)

^c Highmark Inc   (United States)

^d HEALTHCORE INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Blue Cross Blue Shield of North Carolina   (United States)

Author keywords

Health services research; Pharmacology blockers; Pharmacology drug adherence; Statistics and research methods; Survival analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HEART INFARCTION; HUMAN; INSURANCE; MALE; MIDDLE AGED; MORTALITY; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL; TIME; VALIDATION STUDY;

ADRENERGIC BETA-ANTAGONISTS; AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INSURANCE CLAIM REPORTING; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 70449369621     PISSN: 10628606     EISSN: 1555824X     Source Type: Journal    
DOI: 10.1177/1062860609345003     Document Type: Article

References (33)

1. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, DC: US Government Printing Office; 2000.
2. National Center for Health Statistics. Mortality tables. http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs.htm. Updated October 15, 2008. Accessed August 3, 2009.
3. Gottlieb SS, McCarter RJ, Vogel RA Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-498.
4. Krumholz HM, Radford MJ, Wang Y., Chen J., Heiat A., Marciniak TA National use and effectiveness of b-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA. 1998;280:623-629.
5. Soumerai SB, McLaughlin TJ, Spiegelman D., Hertzmark E., Thibault G., Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997; 277:115-121.
6. Ryan TJ, Antman EM, Brooks NH,et al.ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890-911.
7. National Committee for Quality Assurance. The State of Managed Care Quality, 2000. Washington, DC: National Committee for Quality Assurance; 2000.
8. National Committee for Quality Assurance. The State of Health Care Quality, 2003. Washington, DC: National Committee for Quality Assurance; 2003.
9. Agency for Healthcare Research and Quality. National Healthcare Quality Report. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
10. Kramer JM, Hammill B., Anstom KJ,et al.National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454.e1-454.e8.
11. Freemantle N., Cleland J., Young P., Mason J., Harrison J. β-Blocker after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
12. Gallagher EJ, Viscoli CM, Horwitz RI The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. 1993;270:742-744.
13. Horwitz RI, Viscoli CM, Berkman L.,et al.Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542-545.
14. Rasmussen JN, Chong A., Alter DA Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297:177-186.
15. Wei L., Flynn R., Murray GD, MacDonald TM Use and adherence to beta blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf. 2004;13:761-766.
16. Schiele F., Meneveau N., Seronde MF,et al.Compliance with guidelines and 1-year mortality in patients with acute myocardial infarction: a prospective study. Eur Heart J. 2005;26:873-880.
17. Simpson SH, Eurich DT, Majumdar SR,et al.A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
18. Ash AS, Posner MA, Speckman J., Franco S., Yacht AC, Bramwell L. Using claims data to examine mortality trends following hospitalization for heart attack in Medicare. Health Serv Res. 2003;38:1253-1262.
19. Wosinska M. Direct-to-consumer advertising and drug therapy compliance. J Mark Res. 2005;42:323-332.
20. Steiner JF, Prochazka AV The assessment of refill compliance using pharmacy records: methods, validity, and application. J Clin Epidemiol. 1997;50:105-116.
21. Grymonpre R., Cheang M., Fraser M., Metge C., Sitar DS Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44:471-477.
22. Verisk HealthCare. Research and resources: DxCG methodology. www.dxcg.com/research-resources/index.asp. Published 2005. Accessed August 3, 2009.
23. Zhao Y., Ash A., Ellis R.,et al.Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care. 2005;43:34-43.
24. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data (pp 243-248). New York, NY: John Wiley; 1999.
25. The beta-blocker heart attack trial: beta-Blocker Heart Attack Study Group. JAMA. 1981;246:2073-2074.
26. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
27. Hjalmarson A., Elmfeldt D., Herlitz J.,et al.Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823-827.
28. Pedersen TR Six-year follow-up of the Norwegian Multicenter Study on timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055-1058.
29. Furberg CD, Byington RP What do subgroup analyses reveal about differential response to beta-blocker therapy? The beta-blocker heart attack trial experience. Circulation. 1983;67(6, pt 2):198-1101.
30. Aspirin, beta-blocker usage up, but not enough [press release]. Durham, NC: Duke University Medical Center; May 16, 2004.
31. Eagle KA, Kline-Rogers E., Goodman SG,et al.Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117:73-81.
32. Butler J., Arbogast PG, BeLue R.,et al.Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-1595.
33. Simpson E., Beck C., Richard H., Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438-444.